Barclays analyst Balaji Prasad assigned a Buy rating to Coherus Biosciences (CHRS – Research Report) on January 19 and set a price target of $7.00. The company’s shares opened today at $2.73.
Prasad covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Idexx Laboratories, and Pacira Pharmaceuticals. According to TipRanks, Prasad has an average return of 1.4% and a 45.49% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $11.57 average price target, a 323.81% upside from current levels. In a report released on January 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.39 and a one-year low of $1.43. Currently, Coherus Biosciences has an average volume of 7.08M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus Biosciences (CHRS) Company Description:
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS:
- M & A News: Coherus (NASDAQ:CHRS) Surges after $170M Deal with Sandoz
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Biosciences presents positive Phase 2 data on casdozokitu
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
- Inovio, Coherus Biosciences announces clinical collaboration
